Uridine Monophosphate
Pyrimidine nucleotide involved in RNA synthesis and phospholipid membrane production. Synergistic with DHA and choline for synaptogenesis. Converted to UTP/CTP in the brain, promoting phosphatidylcholine synthesis. Short half-life (~2-2.5h) means plasma levels return to baseline by 8 hours. Also enhances dopamine release.
Projected serum levels — 250 mg, once daily
Maintenance schedule: 250 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 106 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 250 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Nootropic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 1.4 h
- Common dose
- 250 mg
- Suggested maximum
- 1k mg/day
- Reference dose range
- 125–1k mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils
Co-administration of uridine with DHA and choline synergistically improved performance on radial arm, T-maze, and Y-maze tests beyond DHA alone, demonstrating synaptogenic synergy.
-
Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats
UMP supplementation in aged rats significantly increased striatal dopamine release and enhanced NGF-induced neurite outgrowth, supporting its role in synaptic plasticity and dopaminergic function.
-
Open-label uridine for treatment of depressed adolescents with bipolar disorder
Pilot open-label trial in 7 depressed bipolar adolescents showed uridine (500 mg BID for 6 weeks) significantly improved depressive symptoms as measured by CDRS-R scores.
3 published studies referenced in the app, each with a plain-language summary.